logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Chronic Obstructive Airway Disease

    FiltersReset Filters
    7 results

    • breo ellipta

      (fluticasone furoate and vilanterol trifenatate)
      GlaxoSmithKline LLC
      Usage: BREO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 5 years and older. It is not to be used for the relief of acute bronchospasm.

    • incruse ellipta

      (umeclidinium)
      GlaxoSmithKline LLC
      Usage: INCRUSE ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients.

    • nucala

      (mepolizumab)
      GlaxoSmithKline LLC
      Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.

    • perforomist

      (formoterol fumarate dihydrate)
      Mylan Specialty L.P.
      Usage: PERFOROMIST (formoterol fumarate) is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, administered twice daily. It is not intended for acute worsening of COPD or for asthma treatment.

    • stiolto respimat

      (tiotropium bromide and olodaterol)
      Boehringer Ingelheim Pharmaceuticals Inc.
      Usage: STIOLTO RESPIMAT is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for acute COPD deteriorations or for the treatment of asthma.

    • trelegy ellipta

      (fluticasone furoate, umeclidinium bromide and vilanterol trifenatate)
      GlaxoSmithKline LLC
      Usage: TRELEGY ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 18 and older. It is not intended for the relief of acute bronchospasm.

    • yupelri

      (revefenacin)
      Mylan Specialty L.P.
      Usage: YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).